Transgenic Models of Heart Failure: Elucidation of the Molecular Mechanisms of Heart Disease

Heart Failure Clinics

Volumn 1, Issue 2, 2005, Pages 219-236

  Lebeche, Djamel ^a   Dalal, Rishikesh ^a   Jang, Monica ^a   del Monte, Federica ^a   Hajjar, Roger J ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR KINASE; CALCINEURIN; CALCINEURIN INHIBITOR; CALCIUM CHANNEL L TYPE; CALSEQUESTRIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOSPORIN; DESMIN; ENZYME; JUNCTIN PROTEIN; MEMBRANE PROTEIN; MYOSIN BINDING PROTEIN C; NERVE GROWTH FACTOR; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; POTASSIUM CHANNEL; PROTEIN; PROTEIN KINASE (CALCIUM,CALMODULIN) II; PROTEIN KINASE C BETA; PROTEIN SERCA1; PROTEIN SERCA2; SERUM RESPONSE FACTOR; SODIUM CALCIUM EXCHANGE PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA2; TRIADIN PROTEIN; TROPOMODULIN; TROPONIN; TSUKUBAENOLIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; CALCIUM TRANSPORT; CYTOSKELETON; DISEASE MODEL; EXPERIMENTAL MODEL; FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; GENE MUTATION; HEART DISEASE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; MOLECULAR MECHANICS; MYOFILAMENT; MYOPATHY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; REVIEW; SARCOMERE; TRANSGENIC ANIMAL;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; DISEASE MODELS, ANIMAL; HEART FAILURE, CONGESTIVE; HUMANS; MODELS, GENETIC;

EID: 33751165052     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.03.005     Document Type: Review

References (92)

1. Smith H.J., and Nuttall A. Experimental models of heart failure. Cardiovasc Res 19 (1985) 181-186
2. Gwathmey J.K. Experimental cardiomyopathies. In: Braunwald E., and Abelman W.H. (Eds). Atlas of heart disease: cardiomyopathies, myocarditis, pericardial disease (1994), Current Medicine, Philadelphia 11.1-11.21
3. Hongo M., Royke T., and Ross J. Animal models of heart failure: recent developments and perspectives. Trends Cardiovasc Med 7 (1997) 161-167
4. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 39 (1998) 60-76
5. James J., Hewett T., and Robbins J. Cardiac physiology in transgenic mice. Circ Res 82 (1998) 407-415
6. Sugawara M., Kato K., Komatsu M., et al. A novel de novo mutation in the desmin gene causes desmin myopathy with toxic aggregates. Neurology 55 7 (2000) 986-990
7. Wang X., Osinska H., Dorn II G.W., et al. Mouse model of desmin-related cardiomyopathy. Circulation 103 19 (2001) 2402-2407
8. Sussman M.A., Welch S., Cambon N., et al. Myofibril degeneration caused by tropomodulin overexpression leads to dilated cardiomyopathy in juvenile mice. J Clin Invest 101 1 (1998) 51-61
9. Subramaniam A., Jones W.K., Gulick J., et al. Tissue-specific regulation of the alpha- myosin heavy chain gene promoter in transgenic mice. J Biol Chem 266 (1991) 24613-24620
10. Huang X., Pi Y., Lee K.J., et al. Cardiac troponin I gene knockout: a mouse model of myocardial troponin I deficiency. Circ Res 84 1 (1999) 1-8
11. Geisterfer-Lowrance A.A., Christe M., Conner D.A., et al. A mouse model of familial hypertrophic cardiomyopathy. Science 272 5262 (1996) 731-734
12. Fatkin D., McConnell B.K., Mudd J.O., et al. An abnormal Ca(2 +) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 106 11 (2000) 1351-1359
13. McConnell B.K., Fatkin D., Semsarian C., et al. Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res 88 4 (2001) 383-389
14. Witt C.C., Gerull B., Davies M.J., et al. Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C. J Biol Chem 276 7 (2001) 5353-5359
15. McConnell B.K., Jones K.A., Fatkin D., et al. Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice [erratum in J Clin Invest 1999;104(12):1771]. J Clin Invest 104 9 (1999) 1235-1244
16. Frank K., Tilgmann C., Shannon T.R., et al. Regulatory role of phospholamban in the efficiency of cardiac sarcoplasmic reticulum Ca2 + transport. Biochemistry 39 46 (2000) 14176-14182
17. Shannon T.R., Chu G., Kranias E.G., et al. Phospholamban decreases the energetic efficiency of the sarcoplasmic reticulum Ca pump. J Biol Chem 276 10 (2001) 7195-7201
18. Luo W., Grupp I.L., Harrer J., et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ Res 75 3 (1994) 401-409
19. Luo W., Wolska B.M., Grupp I.L., et al. Phospholamban gene dosage effects in the mammalian heart. Circ Res 78 5 (1996) 839-847
20. Hoit B.D., Khoury S.F., Kranias E.G., et al. In vivo echocardiographic detection of enhanced left ventricular function in gene-targeted mice with phospholamban deficiency. Circ Res 77 3 (1995) 632-637
21. Chu G., Luo W., Slack J.P., et al. Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ Res 79 6 (1996) 1064-1076
22. Slack J.P., Grupp I.L., Dash R., et al. The enhanced contractility of the phospholamban-deficient mouse heart persists with aging. J Mol Cell Cardiol 33 5 (2001) 1031-1040
23. Wellman G.C., Santana L.F., Bonev A.D., et al. Role of phospholamban in the modulation of arterial Ca(2 +) sparks and Ca(2 +)-activated K(+) channels by cAMP. Am J Physiol Cell Physiol 281 3 (2001) C1029-C1037
24. Kiriazis H., Sato Y., Kadambi V.J., et al. Hypertrophy and functional alterations in hyperdynamic phospholamban-knockout mouse hearts under chronic aortic stenosis. Cardiovasc Res 53 2 (2002) 372-381
25. Brittsan A.G., Carr A.N., Schmidt A.G., et al. Maximal inhibition of SERCA2 Ca(2 +) affinity by phospholamban in transgenic hearts overexpressing a non-phosphorylatable form of phospholamban. J Biol Chem 275 16 (2000) 12129-12135
26. Li Y., Kranias E.G., Mignery G.A., et al. Protein kinase A phosphorylation of the ryanodine receptor does not affect calcium sparks in mouse ventricular myocytes. Circ Res 90 3 (2002) 309-316
27. Kadambi V.J., Ponniah S., Harrer J.M., et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J Clin Invest 97 2 (1996) 533-539
28. Loukianov E., Ji Y., Grupp I.L., et al. Enhanced myocardial contractility and increased Ca2 + transport function in transgenic hearts expressing the fast-twitch skeletal muscle sarcoplasmic reticulum Ca2 + -ATPase. Circ Res 83 9 (1998) 889-897
29. Ji Y., Loukianov E., Loukianova T., et al. SERCA1a can functionally substitute for SERCA2a in the heart. Am J Physiol 276 1 Pt 2 (1999) H89-H97
30. He H., Giordano F.J., Hilal-Dandan R., et al. Overexpression of the rat sarcoplasmic reticulum Ca2 + ATPase gene in the heart of transgenic mice accelerates calcium transients and cardiac relaxation. J Clin Invest 100 2 (1997) 380-389
31. East J.M. Sarco(endo)plasmic reticulum calcium pumps: recent advances in our understanding of structure/function and biology. Mol Membr Biol 17 4 (2000) 189-200 [review]
32. Frank K.F., Bolck B., Brixius K., et al. Modulation of SERCA: implications for the failing human heart. Basic Res Cardiol 97 Suppl 1 (2002) I72-I78
33. Cho M.C., Rapacciuolo A., Koch W.J., et al. Defective β-adrenergic receptor signaling precedes the development of dilated cardiomyopathy in transgenic mice with calsequestrin overexpression. J Biol Chem 274 (1999) 22251-22256
34. Jones L.R., Suzuki Y.J., Wang W., et al. Regulation of Ca2+ signaling in transgenic mouse cardiac myocytes overexpressing calsequestrin. J Clin Invest 101 (1998) 1385-1393
35. Sato Y., Ferguson D.G., Sako H., et al. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. J Biol Chem 273 (1998) 28470-28477
36. Schmidt A.G., Kadambi V.J., Ball N., et al. Cardiac-specific overexpression of calsequestrin results in left ventricular hypertrophy, depressed force-frequency relation and pulsus alternans in vivo. J Mol Cell Cardiol 32 9 (2000) 1735-1744
37. Hong C.S., Cho M.C., Kwak Y.G., et al. Cardiac remodeling and atrial fibrillation in transgenic mice overexpressing junctin. FASEB J 16 10 (2002) 1310-1312
38. Zhang L., Franzini-Armstrong C., Ramesh V., et al. Structural alterations in cardiac calcium release units resulting from overexpression of junctin. J Mol Cell Cardiol 33 2 (2001) 233-247
39. Kirchhefer U., Neumann J., Baba H.A., et al. Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1. J Biol Chem 276 6 (2001) 4142-4149
40. Wickenden A.D., Lee P., Sah R., et al. Targeted expression of a dominant-negative K(v)4.2 K(+) channel subunit in the mouse heart. Circ Res 85 11 (1999) 1067-1076
41. Hasenfuss G. Alterations of calcium-regulatory proteins in heart failure. Cardiovasc Res 37 (1998) 279-289
42. 2+ exchanger in end-stage human heart failure. Circ Res 75 (1994) 443-453
43. 2+-ATPase in ventricular myocytes from transgenic mice. Cardiovasc Res 49 1 (2001) 38-47
44. Baumer A.T., Flesch M., Kilter H., et al. Overexpression of the Na(+)-Ca2+ exchanger leads to enhanced inotropic responsiveness to Na(+)-channel agonist without sarcoplasmic reticulum protein changes in transgenic mice. Biochem Biophys Res Commun 249 3 (1998) 786-790
45. Min J.Y., Sullivan M.F., Yan X., et al. Overexpression of Na+/Ca2+ exchanger gene attenuates postinfarction myocardial dysfunction. Am J Physiol Heart Circ Physiol 283 6 (2002) H2466-H2471
46. Serikov V., Bodi I., Koch S.E., et al. Mice with cardiac-specific sequestration of the beta-subunit of the L-type calcium channel. Biochem Biophys Res Commun 293 5 (2002) 1405-1411
47. Song L.S., Guia A., Muth J.N., et al. Ca(2+) signaling in cardiac myocytes overexpressing the alpha(1) subunit of L-type Ca(2 +) channel. Circ Res 90 2 (2002) 174-181
48. Muth J.N., Yamaguchi H., Mikala G., et al. Cardiac-specific overexpression of the alpha(1) subunit of the L-type voltage-dependent Ca(2 +) channel in transgenic mice. Loss of isoproterenol-induced contraction. J Biol Chem 274 31 (1999) 21503-21506
49. Fentzke R.C., Korcarz C.E., Lang R.M., et al. Dilated cardiomyopathy in transgenic mice expressing a dominant-negative CREB transcription factor in the heart. J Clin Invest 101 (1998) 2415-2426
50. Zhang X., Azhar G., Chai J., et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am J Physiol Heart Circ Physiol 280 4 (2001) H1782-H1792
51. Chu G., Carr A.N., Young K.B., et al. Enhanced myocyte contractility and Ca2 + handling in a calcineurin transgenic model of heart failure. Cardiovasc Res 54 1 (2002) 105-116
52. Molkentin J.D., Lu J.R., Antos C.L., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 2 (1998) 215-228
53. Klee C.B., Ren H., and Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem 273 22 (1998) 13367-13370
54. Lim H.W., De Windt L.J., Mante J., et al. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol 32 4 (2000) 697-709
55. Sussman M.A., Lim H.W., Gude N., et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281 5383 (1998) 1690-1693
56. De Windt L.J., Lim H.W., Bueno O.F., et al. Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo. Proc Natl Acad Sci USA 98 6 (2001) 3322-3327
57. Koch W.J., Rockman H.A., Samama P., et al. Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. Science 268 (1995) 1350-1353
58. Koch W.J., and Rockman H.A. Exploring the role of the beta-adrenergic receptor kinase in cardiac disease using gene- targeted mice. Trends Cardiovasc Med 9 3-4 (1999) 77-81 [review]
59. Shioi T., Kang P.M., Douglas P.S., et al. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J 19 11 (2000) 2537-2548
60. Shioi T., McMullen J.R., Kang P.M., et al. Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22 8 (2002) 2799-2809
61. Matsui T., Li L., Wu J.C., et al. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J Biol Chem 277 25 (2002) 22896-22901
62. Naga Prasad S.V., Esposito G., Mao L., et al. Gβγ-dependent phosphoinositide 3-kinase activation in hearts with in vivo pressure overload hypertrophy. J Biol Chem 275 7 (2000) 4693-4698
63. Wu Y., Temple J., Zhang R., et al. Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. Circulation 106 10 (2002) 1288-1293
64. Zeng J., and Rudy Y. Early afterdepolarizations in cardiac myocytes: mechanism and rate dependence. Biophys J 68 (1995) 949-964
65. Alden K.J., Goldspink P.H., Ruch S.W., et al. Enhancement of L-type Ca(2+) current from neonatal mouse ventricular myocytes by constitutively active PKC-betaII. Am J Physiol Cell Physiol 282 4 (2002) C768-C774
66. Bartram U., Molin D.G., Wisse L.J., et al. Double-outlet right ventricle and overriding tricuspid valve reflect disturbances of looping, myocardialization, endocardial cushion differentiation, and apoptosis in TGF-beta(2)-knockout mice. Circulation 103 22 (2001) 2745-2752
67. Dunker N., and Krieglstein K. Targeted mutations of transforming growth factor-beta genes reveal important roles in mouse development and adult homeostasis. Eur J Biochem 267 24 (2000) 6982-6988 [review]
68. Hassankhani A., Steinhelper M.E., Soonpaa M.H., et al. Overexpression of NGF within the heart of transgenic mice causes hyperinnervation, cardiac enlargement, and hyperplasia of ectopic cells. Dev Biol 169 (1995) 309-321
69. Kajstura J., Fiordaliso F., Andreoli A.M., et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 50 6 (2001) 1414-1424
70. Li B., Setoguchi M., Wang X., et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 84 9 (1999) 1007-1019
71. Li Q., Li B., Wang X., et al. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 100 8 (1997) 1991-1999
72. Reiss K., Cheng W., Ferber A., et al. Overexpression of insulin-like growth factor-1 in the heart is coupled with myocyte proliferation in transgenic mice. Proc Natl Acad Sci USA 93 16 (1996) 8630-8635
73. Colbert M.C., Hall D.G., Kimball T.R., et al. Cardiac compartment-specific overexpression of a modified retinoic acid receptor produces dilated cardiomyopathy and congestive heart failure in transgenic mice. J Clin Invest 100 8 (1997) 1958-1968
74. Hirota H., Chen J., Betz U.A.K., et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97 (1999) 189-198
75. Bryant D., Becker L., Richardson J., et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation 97 14 (1998) 1375-1381
76. Adams J.W., Sakata Y., Davis M.G., et al. Enhanced Galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci USA 95 17 (1998) 10140-10145
77. Wettschureck N., Rutten H., Zywietz A., et al. Absence of pressure overload induced myocardial hypertrophy after conditional inactivation of Galphaq/Galpha11 in cardiomyocytes. Nat Med 7 11 (2001) 1236-1240
78. Iwase M., Uechi M., Vatner D.E., et al. Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol 272 1 Pt 2 (1997) H585-H589
79. Engelhardt S., Boknik P., Keller U., et al. Early impairment of calcium handling and altered expression of junctin in hearts of mice overexpressing the beta1-adrenergic receptor. FASEB J 15 14 (2001) 2718-2720
80. Milano C.A., Dolber P.C., Rockman H.A., et al. Myocardial expression of a constitutively active alpha 1B-adrenergic receptor in transgenic mice induces cardiac hypertrophy. Proc Natl Acad Sci USA 91 21 (1994) 10109-10113
81. Port J.D., and Bristow M.R. Altered beta-adrenergic receptor gene regulation and signaling in chronic heart failure. J Mol Cell Cardiol 33 5 (2001) 887-905
82. Rockman H.A., Koch W.J., and Lefkowitz R.J. Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. Am J Physiol 272 4 Pt 2 (1997) H1553-H1559 [review]
83. Georget M., Mateo P., Vandecasteele G., et al. Augmentation of cardiac contractility with no change in L-type Ca2 + current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8). FASEB J 16 12 (2002) 1636-1638
84. Linck B., Boknik P., Huke S., et al. Functional properties of transgenic mouse hearts overexpressing both calsequestrin and the Na(+)-Ca(2 +) exchanger. J Pharmacol Exp Ther 294 2 (2000) 648-657
85. Sato Y., Kiriazis H., Yatani A., et al. Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation. J Biol Chem 276 12 (2001) 9392-9399
86. Arber S., Hunter J.J., Ross Jr. J., et al. MLP-deficient mice exhibit a disruption of cardiac cytoarchitectural organization, dilated cardiomyopathy, and heart failure. Cell 88 3 (1997) 393-403
87. Omens J.H., Usyk T.P., Li Z., et al. Muscle LIM protein deficiency leads to alterations in passive ventricular mechanics. Am J Physiol Heart Circ Physiol 282 2 (2002) H680-H687
88. Minamisawa S., Hoshijima M., Chu G., et al. Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell 99 3 (1999) 313-322
89. Haghighi K., Gregory K.N., and Kranias E.G. Sarcoplasmic reticulum Ca-ATPase-phospholamban interactions and dilated cardiomyopathy. Biochem Biophys Res Commun 322 4 (2004) 1214-1222
90. Zhao W., Frank K.F., Chu G., et al. Combined phospholamban ablation and SERCA1a overexpression result in a new hyperdynamic cardiac state. Cardiovasc Res 57 1 (2003) 71-81
91. Wolska B.M., Arteaga G.M., Pena J.R., et al. Expression of slow skeletal troponin I in hearts of phospholamban knockout mice alters the relaxant effect of beta-adrenergic stimulation. Circ Res 90 8 (2002) 882-888
92. Hardt S.E., Geng Y.J., Montagne O., et al. Accelerated cardiomyopathy in mice with overexpression of cardiac G(s)alpha and a missense mutation in the alpha-myosin heavy chain. Circulation 105 5 (2002) 614-620